Search clinical trials for: Nonmyeloablative allo-HSCT

Total 127 results

Children's National Research Institute
The Hospital for Sick Children; Ann & Robert H Lurie Children's Hospital of... and other collaborators

Recruiting

Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell AntibodY (SUN-RAY)

Sickle Cell Disease

United States
Peking University People's Hospital

Recruiting

Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction

Acute Leukemia | MDS | CML | MDS/MPN

China
ShiCang Yu
Xinqiao Hospital of Chongqing

Not yet recruiting

Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation

MSC

China
Peking University People's Hospital

Recruiting

Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT

Myelodysplastic Syndromes | Myeloid Leukemia

China
Zhejiang University

Recruiting

Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas

T Lymphoblastic Leukemia/Lymphoma

China
Guangdong Ruishun Biotech Co., Ltd
Anhui Provincial Hospital

Recruiting

RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT

Acute Myeloid Leukemia

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases

Neoplasms | Hematologic Diseases

China
Sichuan University

Recruiting

Fractionated Busulfan Conditioning Regimen for Allo-HSCT in Non-remission Myeloid Malignancies

Myeloid Malignancies

China
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

Sickle Cell Anemia | Beta Thalassemia

United States
National Research Center for Hematology, Russia
Federal Research Clinical Center of Federal Medical & Biological Agency,... and other collaborators

Recruiting

The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission

AML

Russian Federation
University Hospital, Caen

Not yet recruiting

Impact of Allo-HSCT on Bone Remodeling: Evolution of Bone Mineral Density and Architecture Measured by Bone Densitometry (REMODALLO)

Myeloid Leukemia, Acute

France
Vanderbilt University Medical Center
Johns Hopkins University; Emory University; Children's National Research Institute

Recruiting

Cooperative Assessment of Late Effects for SCD Curative Therapies (COALESCE)

Heart Disease | Sickle Cell Disease | Pulmonary Disease | Renal Disease

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Recruiting

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Diffuse Large B-Cell Lymphoma | Acute Myeloid Leukemia | Recurrent Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Recurrent Small Lymphocytic Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm | Prolymphocytic Leukemia and other conditions

United States
University of Calgary

Recruiting

Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor (Sickle-AID)

Sickle Cell Disease | Pure Red Cell Aplasia | Stem Cell Transplant Complications | Red Blood Cell Disorder

Canada
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

Myelodysplastic Syndrome (MDS) | Severe Aplastic Anemia | Hypo-Plastic MDS

United States
National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health Clinical Center (CC); National Cancer Institute...

Recruiting

Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure

Stem Cell Transplantation | Sickle Cell Disease | Thalassemia | Graft vs Host Disease

United States
Washington University School of Medicine
St. Louis Children's Hospital

Recruiting

Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

Hemoglobinopathies | Metabolic Disorders | Hematologic, Immune, or Bone Marrow Disorders | Non-malignant Disorders

United States, Canada
City of Hope Medical Center
California Institute for Regenerative Medicine (CIRM)

Active, not recruiting

A Blood Stem Cell Transplant for Sickle Cell Disease

Sickle Cell Disease | Anemia, Sickle Cell | Hemoglobinopathies | Thalassemia | Sickle Cell Disorder

United States
Cristina Gasparetto
Agilent Technologies, Inc.

Active, not recruiting

Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT (NK-DCI)

Lymphoid Malignancies | Myeloid Malignancies

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients (ELIANA)

B-cell Acute Lymphoblastic Leukemia

United States, Belgium, Germany, Austria, Canada, Italy, Japan, Norway, Australia, France, Spain
St. Petersburg State Pavlov Medical University

Active, not recruiting

Risk-adapted Donor Lymphocyte Infusion After Allo-HSCT in Children With Hematologic Malignancy

Hematologic Malignancy

Russian Federation
Swedish Orphan Biovitrum
PRA Health Sciences; Cromsource; BioMérieux; Q2 Solutions; Cytel Inc.; ABF Pharmaceutical...

Terminated

Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.

Graft Failure

Canada, Australia, Israel
National Heart, Lung, and Blood Institute (NHLBI)

Active, not recruiting

Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease

Sickle Cell Disease

United States
Maisonneuve-Rosemont Hospital

Completed

Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients

Multiple Myeloma | High-Risk Cancer

Canada
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma

Lymphoma

United States
University of Nebraska
National Cancer Institute (NCI)

Withdrawn

Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Nonmalignant Neoplasm

United States
Fred Hutchinson Cancer Center

Terminated

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Recurrent Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Burkitt Lymphoma | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Acute Leukemia in Remission | Acute Undifferentiated Leukemia | Acute Biphenotypic Leukemia and other conditions

United States
Mayo Clinic

Withdrawn

Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Completed

Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)

Lymphoma, Follicular | Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Leukemia, Myeloid, Acute | Burkitt Lymphoma | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

United States
Scripps Health

Completed

Nonmyeloablative Allogeneic Transplant (Mini-allo)

Melanoma | Sarcoma | Renal Cell Carcinoma | Breast Cancer | Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Ovarian Cancer | Thymoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia and other conditions

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

Polycythemia Vera | Essential Thrombocythemia | Chronic Myeloproliferative Disorders | Multiple Myeloma | Myelofibrosis | Chronic Myelomonocytic Leukemia | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Prolymphocytic Leukemia | Plasma Cell Leukemia | Small Lymphocytic Lymphoma and other conditions

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Completed

NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia

Aplastic Anemia | Immunosuppression | Severe Aplastic Anemia | Bone Marrow Failure

United States
Stanford University

Withdrawn

Mixed Chimeric Transplantation for Primary Amyloidosis

Amyloidosis
Washington University School of Medicine

Terminated

Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease

Sickle Cell Disease

United States
University of Liege
KU Leuven; Maastricht University Medical Center

Completed

Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings

Hematological Malignancies

Belgium, Netherlands
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic Syndrome

Severe Aplastic Anemia (SAA) | Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA)

United States
Northside Hospital, Inc.
Millennium Pharmaceuticals, Inc.

Completed

Nonmyeloablative Haploidentical Transplant Followed by MLN9708

Multiple Myeloma | Acute Leukemia | Myelodysplastic Syndrome | Lymphomas | Chronic Leukemia

United States
Robert Lowsky
National Cancer Institute (NCI)

Completed

CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma

Acute Myeloid Leukemia | Hodgkin Lymphoma | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | B-Cell Non-Hodgkin Lymphoma | Myeloproliferative Neoplasm | T-Cell Non-Hodgkin Lymphoma

United States
Shanghai Jiao Tong University School of Medicine

Completed

Low-dose Decitabine for the Treatment of Decreased Donor Chimerism After Allogeneic Stem Cell Transplantation

Response Rate

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Terminated

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders

Genetic Disorder | Severe Aplastic Anemia | Immunodeficiency Syndrome

United States
M.D. Anderson Cancer Center
Spectrum Pharmaceuticals, Inc

Completed

Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

Lymphoma | Leukemia

United States
NYU Langone Health

Terminated

Study of Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Hematopoietic Malignancies Including Those That Are Challenging to Engraft

Hematopoietic Malignancies

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Myeloproliferative Neoplasm | Paroxysmal Nocturnal Hemoglobinuria | de Novo Myelodysplastic Syndrome | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Refractory Anemia | Refractory Anemia With... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Recurrent Disease | Adult Acute Lymphoblastic Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Adult B Acute Lymphoblastic... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

Refractory Hodgkin Lymphoma | Recurrent Adult Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | T-Cell Chronic Lymphocytic Leukemia | Recurrent Childhood Non-Hodgkin... and other conditions

United States, Germany
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia

Previously Treated Myelodysplastic Syndrome | Fanconi Anemia | de Novo Myelodysplastic Syndrome | Acute Myeloid Leukemia in Remission

United States, Brazil
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell... and other conditions

United States, Italy
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic... and other conditions

United States
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Completed

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma

United States

Search clinical trials for: Nonmyeloablative allo-HSCT

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations